This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, M. A. Articles by Johansson, J.-E. Search for Related Content PubMed PubMed Citation Articles by Rubin, M. A. Articles by Johansson, J.-E.

Decreased -Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death

¹ Department of Pathology, Brigham and Women's Hospital, ² Harvard Medical School, ³ Harvard School of Public Health, and ⁴ Dana-Farber Harvard Cancer Center, Boston, Massachusetts; ⁵ Department of Biostatistics, University of Michigan School of Public Health; Departments of ⁶ Urology and ⁷ Pathology, ⁸ University of Michigan Medical School, Ann Arbor, Michigan; ⁹ Department of Urology, Örebro University Hospital, Örebro, Sweden; and ¹⁰ Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

Requests for reprints: Mark A. Rubin, Department of Pathology (Amory 3-195), Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115. Phone: 617-525-6747; Fax: 617-264-5169. E-mail: marubin{at}partners.org

-Methylacyl CoA racemase (AMACR) is overexpressed in prostate cancer relative to benign prostatic tissue. AMACR expression is highest in localized prostate cancer and decreases in metastatic prostate cancer. Herein, we explored the use of AMACR as a biomarker for aggressive prostate cancer. AMACR protein expression was determined by immunohistochemistry using an image analysis system on two localized prostate cancer cohorts consisting of 204 men treated by radical prostatectomy and 188 men followed expectantly. The end points for the cohorts were time to prostate-specific antigen (PSA) failure (i.e., elevation >0.2 ng/mL) and time to prostate cancer death in the watchful waiting cohort. Using a regression tree method, optimal AMACR protein expression cutpoints were determined to best differentiate prostate cancer outcome in each of the cohorts separately. Cox proportional hazard models were then employed to examine the effect of the AMACR cutpoint on prostate cancer outcome, and adjusted for clinical variables. Lower AMACR tissue expression was associated with worse prostate cancer outcome, independent of clinical variables (hazard ratio, 3.7 for PSA failure; P = 0.018; hazard ratio, 4.1 for prostate cancer death, P = 0.0006). Among those with both low AMACR expression and high Gleason score, the risk of prostate cancer death was 18-fold higher (P = 0.006). The AMACR cutpoint developed using prostate cancer–specific death as the end point predicted PSA failures independent of Gleason score, PSA, and margin status. This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer.

This article has been cited by other articles:

				F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF]

				B. Lin, A. G. Utleg, K. Gravdal, J. T. White, O. J. Halvorsen, W. Lu, L. D. True, R. Vessella, P. H. Lange, P. S. Nelson, et al. WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clin. Cancer Res., March 1, 2008; 14(5): 1397 - 1406. [Abstract] [Full Text] [PDF]

				L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. S. Eisenstein, L. Holmberg, et al. Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 249 - 251. [Abstract] [Full Text] [PDF]

				J.-S. Diallo, A. Aldejmah, A. F. Mouhim, B. Peant, M. A. Fahmy, I. H. Koumakpayi, K. Sircar, L. R. Begin, A.-M. Mes-Masson, and F. Saad NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model Clin. Cancer Res., December 1, 2007; 13(23): 7044 - 7052. [Abstract] [Full Text] [PDF]

				S. R. Setlur, T. E. Royce, A. Sboner, J.-M. Mosquera, F. Demichelis, M. D. Hofer, K. D. Mertz, M. Gerstein, and M. A. Rubin Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10296 - 10303. [Abstract] [Full Text] [PDF]

				J. Banyard, L. Bao, M. D. Hofer, D. Zurakowski, K. A. Spivey, A. S. Feldman, L. M. Hutchinson, R. Kuefer, M. A. Rubin, and B. R. Zetter Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases Clin. Cancer Res., May 1, 2007; 13(9): 2634 - 2642. [Abstract] [Full Text] [PDF]

				P. J.M. Hendriksen, N. F.J. Dits, K. Kokame, A. Veldhoven, W. M. van Weerden, C. H. Bangma, J. Trapman, and G. Jenster Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer. Cancer Res., May 15, 2006; 66(10): 5012 - 5020. [Abstract] [Full Text] [PDF]

				I. Krop, A. Marz, H. Carlsson, X. Li, N. Bloushtain-Qimron, M. Hu, R. Gelman, M. S. Sabel, S. Schnitt, S. Ramaswamy, et al. A Putative Role for Psoriasin in Breast Tumor Progression Cancer Res., December 15, 2005; 65(24): 11326 - 11334. [Abstract] [Full Text] [PDF]